Synopsis
Synopsis
0
VMF
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Polymyxin B, Sulfate (salt)
2. 1405-20-5
3. Polymixin B Sulphate
4. Ks-1428
5. Pmb
6. Akos025392172
7. Polymyxin B Sulfate, Bacillus Polymyxa
8. M02428
9. Polymyxin B Sulfate (1404-26-8 Free Base)
10. 405p205
| Molecular Weight | 1301.6 g/mol |
|---|---|
| Molecular Formula | C56H100N16O17S |
| Hydrogen Bond Donor Count | 20 |
| Hydrogen Bond Acceptor Count | 22 |
| Rotatable Bond Count | 29 |
| Exact Mass | 1300.71730696 g/mol |
| Monoisotopic Mass | 1300.71730696 g/mol |
| Topological Polar Surface Area | 574 Ų |
| Heavy Atom Count | 90 |
| Formal Charge | 0 |
| Complexity | 2240 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 12 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Polymyxin b sulfate |
| Drug Label | Polymyxin B for Injection, USP is one of a group of basic polypeptide antibiotics derived from B polymyxa (B aerosporous). Polymyxin B sulfate is the sulfate salt of Polymyxins B1 and B2, which are produced by the growth of Bacillus polymyxa (Prazmow... |
| Active Ingredient | Polymyxin b sulfate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 500,000 u base/vial |
| Market Status | Prescription |
| Company | X Gen Pharms; Xellia Pharms Aps; Fresenius Kabi Usa; Eurohlth Intl |
| 2 of 2 | |
|---|---|
| Drug Name | Polymyxin b sulfate |
| Drug Label | Polymyxin B for Injection, USP is one of a group of basic polypeptide antibiotics derived from B polymyxa (B aerosporous). Polymyxin B sulfate is the sulfate salt of Polymyxins B1 and B2, which are produced by the growth of Bacillus polymyxa (Prazmow... |
| Active Ingredient | Polymyxin b sulfate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 500,000 u base/vial |
| Market Status | Prescription |
| Company | X Gen Pharms; Xellia Pharms Aps; Fresenius Kabi Usa; Eurohlth Intl |
GDUFA
DMF Review : Reviewed
Rev. Date : 2012-11-08
Pay. Date : 2012-10-31
DMF Number : 13536
Submission : 1998-09-01
Status : Active
Type : II
Certificate Number : CEP 1998-061 - Rev 06
Issue Date : 2026-01-22
Type : Chemical
Substance Number : 203
Status : Valid
Registration Number : 219MF10071
Registrant's Address : Dalslandsgade 11, DK-2300 Copenhagen-S, Denmark
Initial Date of Registration : 2007-03-14
Latest Date of Registration :
NDC Package Code : 45932-0002
Start Marketing Date : 1999-06-10
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Novartis Korea
Registration Date : 2023-08-11
Registration Number : 20210317-211-J-890(A)
Manufacturer Name : Xellia Pharmaceuticals ApS
Manufacturer Address : Dalslandsgade 11, 2300 Copenhagen S, Denmark
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
BV100 is a antibiotic drug, which is currently being evaluated in Phase I clinical studies for the treatment of undisclosed medical condition.
Lead Product(s): BV100,Polymyxin B Sulfate
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 12, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BV100,Polymyxin B Sulfate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BV100 is a antibiotic drug, which is currently being evaluated in Phase I clinical studies for the treatment of undisclosed medical condition.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 12, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
VRP-034 (Polymyxin B) is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of undisclosed medical condition.
Lead Product(s): Polymyxin B Sulfate,Inapplicable
Therapeutic Area: Undisclosed Brand Name: VRP-034
Study Phase: Phase IProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 30, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Polymyxin B Sulfate,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VRP-034 (Polymyxin B) is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of undisclosed medical condition.
Product Name : VRP-034
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 30, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
BV100 (Rifabutin) is a antibiotic drug, which is currently being evaluated in Phase II clinical studies for the treatment of pneumonia, ventilator-associated.
Lead Product(s): Rifabutin,Polymyxin B Sulfate,Ceftazidime,Avibactam,Cefiderocol
Therapeutic Area: Infections and Infectious Diseases Brand Name: BV100
Study Phase: Phase IIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 24, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rifabutin,Polymyxin B Sulfate,Ceftazidime,Avibactam,Cefiderocol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BV100 (Rifabutin) is a antibiotic drug, which is currently being evaluated in Phase II clinical studies for the treatment of pneumonia, ventilator-associated.
Product Name : BV100
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 24, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
BV100 (Rifabutin) is a Antibiotic drug, which is currently being evaluated in Phase III clinical studies for the treatment of Healthcare-Associated Pneumonia.
Lead Product(s): Rifabutin,Polymyxin B Sulfate,Meropenem
Therapeutic Area: Infections and Infectious Diseases Brand Name: BV100
Study Phase: Phase IIIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 08, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rifabutin,Polymyxin B Sulfate,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BV100 (Rifabutin) is a Antibiotic drug, which is currently being evaluated in Phase III clinical studies for the treatment of Healthcare-Associated Pneumonia.
Product Name : BV100
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 08, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The partnership aims to launch an Maxitrol-Generic (Neomycin/Polymyxin B Sulfates/Dexamethasone) ophthalmic suspension, which treats and relieves bacterial eye infections.
Lead Product(s): Dexamethasone,Neomycin Sulfate,Polymyxin B Sulfate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Maxitrol-Generic
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Harrow
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 24, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dexamethasone,Neomycin Sulfate,Polymyxin B Sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Harrow
Deal Size : Undisclosed
Deal Type : Partnership
Nordic Pharma Launches Authorized Generic of Maxitrol in the U.S.
Details : The partnership aims to launch an Maxitrol-Generic (Neomycin/Polymyxin B Sulfates/Dexamethasone) ophthalmic suspension, which treats and relieves bacterial eye infections.
Product Name : Maxitrol-Generic
Product Type : Steroid
Upfront Cash : Undisclosed
April 24, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
VRP-034 (polymyxin B sulfate) is an antibiotic that disrupts the outer cell membrane of Gram negative bacteria, being investigated for bloodstream infections caused by PMB susceptible strains.
Lead Product(s): Polymyxin B Sulfate,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 17, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Polymyxin B Sulfate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Venus Remedies VRP-034 receives QIDP designation from US FDA
Details : VRP-034 (polymyxin B sulfate) is an antibiotic that disrupts the outer cell membrane of Gram negative bacteria, being investigated for bloodstream infections caused by PMB susceptible strains.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 17, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The net proceeds from the offering are expected to be primarily used by the company on its late-stage product Toraymyxin (Polymyxin B) for its PMX treatment for endotoxemic septic shock.
Lead Product(s): Polymyxin B Sulfate,Inapplicable
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Toraymyxin
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Paradigm Capital
Deal Size: $8.5 million Upfront Cash: Undisclosed
Deal Type: Financing May 30, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Polymyxin B Sulfate,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Paradigm Capital
Deal Size : $8.5 million
Deal Type : Financing
Spectral Medical Inc. Announces Closing of C$8.5 Million Convertible Notes Financing
Details : The net proceeds from the offering are expected to be primarily used by the company on its late-stage product Toraymyxin (Polymyxin B) for its PMX treatment for endotoxemic septic shock.
Product Name : Toraymyxin
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 30, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The proceeds will primarily support Phase III trial for PMX treatment of endotoxemic septic shock, evaluating Toraymyxin (polymyxin B), a therapeutic hemoperfusion device that removes endotoxin.
Lead Product(s): Polymyxin B Sulfate,Inapplicable
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Toraymyxin
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Paradigm Capital
Deal Size: $6.2 million Upfront Cash: Undisclosed
Deal Type: Financing May 09, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Polymyxin B Sulfate,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Paradigm Capital
Deal Size : $6.2 million
Deal Type : Financing
Spectral Medical Inc. Announces C$8.5 Million Bought Deal Convertible Note Financing
Details : The proceeds will primarily support Phase III trial for PMX treatment of endotoxemic septic shock, evaluating Toraymyxin (polymyxin B), a therapeutic hemoperfusion device that removes endotoxin.
Product Name : Toraymyxin
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 09, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Toraymyxin (Polymyxin B) is a small molecule drug candidate which is shown to inhibit bacterial respiration. It is being evaluated for the treatment of septic shock.
Lead Product(s): Polymyxin B Sulfate,Inapplicable
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Toraymyxin
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 10, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Polymyxin B Sulfate,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Spectral Medical Provides Tigris Trial Update
Details : Toraymyxin (Polymyxin B) is a small molecule drug candidate which is shown to inhibit bacterial respiration. It is being evaluated for the treatment of septic shock.
Product Name : Toraymyxin
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 10, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Baxter holds exclusive rights to commercialize Toraymyxin (polymyxin B), a therapeutic device removing endotoxins from the bloodstream, guided by Spectral’s Endotoxin Activity Assay.
Lead Product(s): Polymyxin B Sulfate,Inapplicable
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Toraymyxin
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Baxter Healthcare Corporation
Deal Size: Undisclosed Upfront Cash: $5.0 million
Deal Type: Agreement February 21, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Polymyxin B Sulfate,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Baxter Healthcare Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Spectral Medical Extends Exclusive Supply Agreement with Baxter Healthcare
Details : Baxter holds exclusive rights to commercialize Toraymyxin (polymyxin B), a therapeutic device removing endotoxins from the bloodstream, guided by Spectral’s Endotoxin Activity Assay.
Product Name : Toraymyxin
Product Type : Miscellaneous
Upfront Cash : $5.0 million
February 21, 2024

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Reply
09 May 2026
Reply
07 May 2026
Reply
10 Nov 2025
Reply
10 Jun 2025
Reply
21 Feb 2025
Reply
16 Dec 2024
Reply
13 Nov 2024
Reply
22 Aug 2024
Reply
08 May 2024
Reply
03 Jan 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
21
PharmaCompass offers a list of Polymyxin B Sulfate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Polymyxin B Sulfate manufacturer or Polymyxin B Sulfate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Polymyxin B Sulfate manufacturer or Polymyxin B Sulfate supplier.
A POLY-RX manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of POLY-RX, including repackagers and relabelers. The FDA regulates POLY-RX manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. POLY-RX API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of POLY-RX manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A POLY-RX supplier is an individual or a company that provides POLY-RX active pharmaceutical ingredient (API) or POLY-RX finished formulations upon request. The POLY-RX suppliers may include POLY-RX API manufacturers, exporters, distributors and traders.
click here to find a list of POLY-RX suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A POLY-RX DMF (Drug Master File) is a document detailing the whole manufacturing process of POLY-RX active pharmaceutical ingredient (API) in detail. Different forms of POLY-RX DMFs exist exist since differing nations have different regulations, such as POLY-RX USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A POLY-RX DMF submitted to regulatory agencies in the US is known as a USDMF. POLY-RX USDMF includes data on POLY-RX's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The POLY-RX USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of POLY-RX suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The POLY-RX Drug Master File in Japan (POLY-RX JDMF) empowers POLY-RX API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the POLY-RX JDMF during the approval evaluation for pharmaceutical products. At the time of POLY-RX JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of POLY-RX suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a POLY-RX Drug Master File in Korea (POLY-RX KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of POLY-RX. The MFDS reviews the POLY-RX KDMF as part of the drug registration process and uses the information provided in the POLY-RX KDMF to evaluate the safety and efficacy of the drug.
After submitting a POLY-RX KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their POLY-RX API can apply through the Korea Drug Master File (KDMF).
click here to find a list of POLY-RX suppliers with KDMF on PharmaCompass.
A POLY-RX CEP of the European Pharmacopoeia monograph is often referred to as a POLY-RX Certificate of Suitability (COS). The purpose of a POLY-RX CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of POLY-RX EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of POLY-RX to their clients by showing that a POLY-RX CEP has been issued for it. The manufacturer submits a POLY-RX CEP (COS) as part of the market authorization procedure, and it takes on the role of a POLY-RX CEP holder for the record. Additionally, the data presented in the POLY-RX CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the POLY-RX DMF.
A POLY-RX CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. POLY-RX CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of POLY-RX suppliers with CEP (COS) on PharmaCompass.
A POLY-RX written confirmation (POLY-RX WC) is an official document issued by a regulatory agency to a POLY-RX manufacturer, verifying that the manufacturing facility of a POLY-RX active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting POLY-RX APIs or POLY-RX finished pharmaceutical products to another nation, regulatory agencies frequently require a POLY-RX WC (written confirmation) as part of the regulatory process.
click here to find a list of POLY-RX suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing POLY-RX as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for POLY-RX API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture POLY-RX as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain POLY-RX and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a POLY-RX NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of POLY-RX suppliers with NDC on PharmaCompass.
POLY-RX Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of POLY-RX GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right POLY-RX GMP manufacturer or POLY-RX GMP API supplier for your needs.
A POLY-RX CoA (Certificate of Analysis) is a formal document that attests to POLY-RX's compliance with POLY-RX specifications and serves as a tool for batch-level quality control.
POLY-RX CoA mostly includes findings from lab analyses of a specific batch. For each POLY-RX CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
POLY-RX may be tested according to a variety of international standards, such as European Pharmacopoeia (POLY-RX EP), POLY-RX JP (Japanese Pharmacopeia) and the US Pharmacopoeia (POLY-RX USP).